G. Brozek (Katowice, Poland), S. Skoczynski (Katowice, Poland), F. Luppi (Spilamberto, Italy)
The combination of low fat-free mass and high fat mass is related to functional outcome and systemic inflammation in patients with COPD
P. Joppa, F. Franssen, R. Tkacova, C. Hanson, S. Rennard, E. Silverman, M. L. McDonald, P. Calverley, E. Wouters, E. Rutten (Horn, Maastricht, Netherlands; Kosice, Slovakia; Omaha, Boston, United States Of America; Liverpool, United Kingdom)
|   |
Assessment of treatment efficiency in patients with chronic obstructive pulmonary disease combined with gastroesophageal reflux disease during treatment with melatonin
V. Kamenir, D. Kalashnyk, O. Korotchenko, E. Hetman (Kharkov, Ukraine)
| |
Roflumilast for stable COPD: Meta-analysis of randomized controlled trials
H. Zeng, Y. Chen (Changsha, China)
| |
Comparison of CAT and CCQ in a clinical COPD population
J. Sundh, B. Ställberg, K. Lisspers, M. Kämpe, C. Janson, S. Montgomery (Örebro, Uppsala, Sweden)
| |
Gender differences in COPD patients
V. Kapustina, S. Ovcharenko (Moscow, Russian Federation)
| |
Impact of frequent exacerbations in patients with COPD
A. Ben Saad, N. Rouatbi, S. Joobeur, N. Skhiri, S. Cheikh Mhamed, H. Mribah, A. El Kamel (Monastir, Tunisia)
| |
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
O. Shtepa, T. Pertseva (Dniproprtrovsk, Ukraine)
| |
Is clinical presentation different between men and women with COPD?
O. Llaguno, I. Murga, D. Bravo, J. García, J. L. Lobo, A. Rivas, P. Sobradillo (Vitoria, Spain)
| |
Prevalence of co-morbidities with chronic obstructive pulmonary disease (COPD) in a primary care cohort
M. Singh (Rugeley, United Kingdom)
| |
The Evaluation of nutritional status of stable COPD patients and to investigate the effect of nutritional status on perception of dyspnea, exercise capacity, body composition, hospitalisation and life quality
G. A. Karakoc, D. Ernam, S. Oztas, U. A. Aktork, E. Ogur (Istanbul, Turkey)
| |
Pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD): Preliminary data of a longitudinal survey
C. Priegnitz, S. Matthes, M. Treml, K. Richter, S. Stieglitz, W. J. Randerath (Solingen, Germany)
| |
Metabolic syndrome in patients with COPD
R. Rubinsztajn, T. Przybylowski, M. Maskey-Warzechowska, M. Paplinska-Goryca, P. Nejman-Gryz, K. Karwat, R. Chazan (Warsaw, Poland)
| |
COPD and concomitant arterial hypertension: The efficacy and safety of slow-release formulation of indapamide
Z. Nersesyan, S. Ovcharenko, T. Morozova (Moscow, Russian Federation)
| |
Peculiarities of intracardiac hemodynamics in patients with chronic obstructive pulmonary disease
E.B. Klester, L.A. Plinokosova, Ya.N. Shoichet, K.V. Klester, O.A. Ivanov (Barnaul, Russian Federation)
| |
COPD and clinical phenotypes: Patients with concomitant pulmonary hypertension may be less likely to be frequent exacerbators
S. Matthes, C. Priegnitz, N. Anduleit, W. J. Randerath (Solingen, Germany)
| |
Signs of rhinosinusitis in a COPD case-control study
C. Gerhards, E. H. Steveling, C. Zaehringer, S. Dürr, N. Abu Hussein, S. Maier, C. Gregoriano, C. Stippich, A. Welge-Lüssen, D. Miedinger, S. Zogg, J. D. Leuppi (Liestal, Basel, Zürich, Switzerland)
| |
Mortality after COPD-exacerbations: Learning from epidemiology
E. Stazzone, S. Pinasco, D. Piñeiro, H. di Fonzo, M. Mazzei (Buenos Aires, Argentina)
| |
Determination of the existence of a correlation between lung function decline and changes in the COPD assessment test
T. Motegi, T. Ishii, K. Hattori, Y. Kusunoki, R. Furutate, A. Gemma, K. Kida (Tokyo, Japan)
| |
BODCAT index: Could we use it instead of BODE or BODEx to classify COPD severity?
E. Ojeda, L. Moran, P. Rodriguez, J. M. Rodriguez, S. Lopez, P. De Lucas (Madrid, Spain)
| |